Alumni Capital

Oncolytics Biotech Inc. is a clinical-stage biopharmaceutical company based in Calgary, Canada, dedicated to the discovery and development of innovative cancer therapies. The company's lead product, pelareorep, is an immuno-oncology agent derived from reovirus, designed to treat solid tumors and hematological malignancies by enhancing the immune system's ability to combat cancer. Oncolytics Biotech has established collaboration agreements with Merck KGaA and Pfizer Inc. to explore pelareorep in combination with other treatments for specific types of breast cancer. Additionally, the company is advancing its pipeline with projects such as Bracelet-1 for breast cancer and various cohorts for gastrointestinal cancer. Founded in 1998, Oncolytics Biotech aims to develop effective treatments for cancers that have not responded to existing therapies.

Safe & Green Holdings is a modular solutions company specializing in the development, design, and fabrication of innovative structures using code-engineered cargo shipping containers and wood. The company caters to the growing demand for safe and environmentally friendly solutions across various industries, including residential housing and commercial applications, such as healthcare facilities. Safe & Green operates in four main segments: construction services, medical, real estate development, and environmental. The majority of its revenue is generated from the construction segment, which includes its manufacturing unit SG ECHO and various modular projects.

V Capital Group is a team of industry experts that provides comprehensive advisory and capital-raising services across the entire capital spectrum. The firm focuses on delivering tailored solutions through its extensive experience and market knowledge, which encompasses various industries. V Capital Group's approach emphasizes a solutions-oriented methodology to corporate advisory engagements, ensuring that clients receive informed guidance and support in their financial endeavors.

V Capital Group is a team of industry experts that provides comprehensive advisory and capital-raising services across the entire capital spectrum. The firm focuses on delivering tailored solutions through its extensive experience and market knowledge, which encompasses various industries. V Capital Group's approach emphasizes a solutions-oriented methodology to corporate advisory engagements, ensuring that clients receive informed guidance and support in their financial endeavors.

Greenbrook TMS Inc. operates a network of outpatient mental health service centers across the United States, specializing in transcranial magnetic stimulation (TMS) therapy. This FDA-cleared, non-invasive treatment offers electromagnetic stimulation to brain regions involved in mood regulation, primarily targeting major depressive disorder and other mental health conditions. Founded in 2011 and headquartered in Toronto, Canada, Greenbrook TMS manages approximately 121 treatment centers nationwide, providing accessible care for individuals seeking innovative solutions for their mental health challenges.

Azitra Inc. is a clinical-stage biopharmaceutical company based in Farmington, Connecticut, specializing in microbiome-based therapeutics for skin diseases. Founded in 2014, Azitra leverages extensive scientific research on the skin microbiome to develop innovative treatments for various adverse skin conditions. The company’s proprietary platform includes a microbial library of engineered bacterial strains, notably Staphylococcus epidermidis, which are screened for therapeutic properties. In collaboration with researchers from Yale University and the Jackson Laboratory, Azitra employs advanced technologies such as artificial intelligence and machine learning to analyze and predict the efficacy of its strains. The company focuses on precision dermatology by developing live biotherapeutic products and engineered proteins for topical application, aiming to address unmet medical needs in the dermatological field.

Brazil Potash aims to invest in a cleaner, sustainable future. Founded in 2009 by both Brazilian and foreign investors, the company’s foundations began with a singular goal to help achieve an independent and local output of potash in Brazil. Brazil Potash has since taken several years of exploratory drilling under proper legislation, complying with environmental studies, preparing and implementing environmental and social programs and consulting local indigenous populations to prepare for the next chapter in this company’s venture. Brazil Potash understands that potash is a key resource for farming. Potash makes soil arable, contributes to long-term farming of the same land plot, and is one of the most important exports for the agricultural sector. However, though Brazil may be one of the world’s largest and fastest-growing markets for potash, currently roughly 95% of its potash is imported from foreign countries. The company plans to begin extraction on its Autazes Potash Project, which is 120 km southeast of Manaus. Brazil Potash aims to make available up to 2,600 direct jobs during its installation phase and 1,300 during its operation phase, as well as 12 times that number in indirect positions. It also stands to connect the municipality to necessary infrastructure for quality of life, and grant the municipality increased tax revenues that can be reinvested into schools, water quality, roads and healthcare services. Brazil Potash has been recognized internationally for its plan to reduce greenhouse gas emissions caused by potash imports by upwards of 65%. Brazil Potash is led by executives who include CEO Matt Simpson, Brazil President Adriano Espeschit, Head of Finance, Davidson Aquino, geology specialists Gustavo Kiefer, Marketing Director Marcos Pedrini, Project Director Rafael Bloise and ESG Director Lúcio Rabelo. Brazil Potash’s technical headquarters is stationed in Autazes. Brazil Potash also includes a corporate office in Toronto, and its administrative branch is located in Manaus and Belo Horizonte, Brazil.